Santhera seeks speedy FDA review of Duchenne drug vamorolone
pharmaphorum
OCTOBER 27, 2022
The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.
Let's personalize your content